Skygenix proudly presents the Annual World NSCLC Summit, (Non-Small Cell Lung Cancer) taking place on January 27th and 28th in the Colonnade Hotel in Boston, USA.
Over the two days, this exclusive summit will bring together over 100 senior level attendees from the pharmaceutical industry to discuss the most crucial challenges in the development of targeted therapies in NSCLC (Non small Cell Lung Cancer).
The segment is forecast to grow from $4.9 billion to over $8.5 billion in 2023, driven by the entry of thirteen novel drugs.
Over the two days the World NSCLC Summit will cover presentations on the latest updates from the NSCLC pipelines of small and large drug developers, and feature discussions around all the latest trends in personalized medicine, as pertaining to this disease area, through case studies from early discovery to commercial development.
Topics Include: Antibody Drug Conjugates, Immunotherapies, Overcoming Resistance to First Line Treatment, Cancer Genomics and Companion Diagnostics.
Over the two days, this exclusive summit will bring together over 100 senior level attendees from the pharmaceutical industry to discuss the most crucial challenges in the development of targeted therapies in NSCLC (Non small Cell Lung Cancer).
The segment is forecast to grow from $4.9 billion to over $8.5 billion in 2023, driven by the entry of thirteen novel drugs.
Over the two days the World NSCLC Summit will cover presentations on the latest updates from the NSCLC pipelines of small and large drug developers, and feature discussions around all the latest trends in personalized medicine, as pertaining to this disease area, through case studies from early discovery to commercial development.
Topics Include: Antibody Drug Conjugates, Immunotherapies, Overcoming Resistance to First Line Treatment, Cancer Genomics and Companion Diagnostics.
